Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
The DOI matches its Crossref record.
Abstract
Beta-endorphin were detected in the endocrine pancreas and seem able to influence insulin and glucagon release. Hence, endogenous opioids could have a role in glucoregulation and in the pathogenesis of obesity beyond the previously detected effects on appetite. Metabolic abnormalities, such as hyperinsulinemia, insulin-resistance and obesity, are common features of polycystic ovary syndrome (PCOS), and seem to have a pathogenetic role in this disorder. A link between opioids and PCOS-related hyperinsulinism is suggested by the finding of altered central opioid tone and elevated beta-endorphins levels, directly correlated with body weight, in these patients. Furthermore, naloxone and naltrexone significantly reduce the insulin response to glucose load only in hyperinsulinemic PCOS patients. This effect is obtained chiefly through an improvement of insulin clearance. Naltrexone is also able to ameliorate the abnormal gonadotrophins secretion and to improve the ovarian responsiveness in obese PCOS women undergoing ovulation induction with exogenous GnRH. Such effects are believed to be obtained through an amelioration of hyperinsulinemia. Gonadal steroids modulate the opioid system both centrally and in peripheral districts. Nevertheless, the decline of ovarian function does not abolish the opioidergic control of glucoregulation. Post-menopausal period is characterised by a high prevalence of hyperinsulinemia and insulin-resistance. In particular, an association between hyperinsulinemia and increased opioid activity was found in postmenopausal women showing a central body fat distribution. Both naloxone and naltrexone ameliorate the metabolic imbalance also when it appears in the climacteric period, and mainly by increasing insulin clearance. The benefits of naltrexone may represent in the future a useful tool for the treatment of women with hyperinsulinism in the clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Basaria, S., Travison, T. G., Alford, D., Knapp, P. E., Teeter, K., Cahalan, C., Eder, R., Lakshman, K., Bachman, E., Mensing, G., et al. (2015) · Pain · doi:10.1097/01.j.pain.0000460308.86819.aa · Cited by 125
Impact of the opioid system on the reproductive axis
Böttcher, B., Seeber, B., Leyendecker, G., & Wildt, L. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.009 · Cited by 115
Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome
Ahmed, M. I., Duleba, A. J., El Shahat, O., Ibrahim, M. E., & Salem, A. (2008) · Human Reproduction · doi:10.1093/humrep/den273 · Cited by 58
“A link between opioids and PCOS-related hyperinsulinism is suggested by the finding of altered central opioid tone evidenced by elevated b-endorphins levels, which directly correlated with body weight (Guido et al., 2006).”
BackgroundThe evolutionary biology of endometriosis
Dinsdale, N., Nepomnaschy, P., & Crespi, B. (2021) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoab008 · Cited by 53
Metadata
- Authors
- Guido, M., Romualdi, D., & Lanzone, A.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-03-01
- Volume
- 12
- Issue
- 8
- Pages
- 1001-1012
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1984120397
- Cited by
- 28
- References
- 0
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities. https://app.cochat.ai/papers/10.2174/138161206776055895
- The paper
- Guido, M., Romualdi, D., & Lanzone, A. (2006). Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities. Current Pharmaceutical Design. https://doi.org/10.2174/138161206776055895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.